Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition
Autolus Therapeutics (Nasdaq: AUTL) will hold a conference call on December 13, 2021, at 8:00 am ET to discuss data presented at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place December 11-14.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will hold a conference call on December 13, 2021, at 8:00 am ET to discuss data presented at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place December 11-14. This call reflects a timing change from the previous announcement. The call will include a webcast with accompanying slides available on the company's website. A replay of the call will be accessible for one week after.
Positive
- Management is engaging with investors through a scheduled call to discuss ASH data, indicating transparency and involvement.
- The company showcases its presence at a significant industry event, which may enhance its visibility and credibility.
Negative
- None.
Details
News Market Reaction – AUTL
The recorded move for AUTL in the trading session of this news was +3.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast to be held on Monday, December 13, 2021 at 8:00 am ET / 1:00 pm GMT
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it will hold a conference call to discuss the data being presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021. Note this is a change to the timing announced previously.
New timing of investor call
Management will host a conference call and webcast on Monday, December 13, 2021, at 8:00 am ET/1:00 pm GMT to discuss the ASH data. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus’ website.
Conference Dial in:
- United States and Canada (866) 679-5407
- International (409) 217-8320
- Conference ID 31044873
Replay:
A replay will be available for one week following the call
- United States and Canada (855) 859-2056
- International (404) 537-3406
- Conference ID 31044873
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.
Contact:
Lucinda Crabtree, PhD
Vice President, Business Strategy and Planning
+44 (0) 7587 372 619
l.crabtree@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.